Panacur Equine Oral Paste 18.75 %w/w

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

Fenbendazole

Inapatikana kutoka:

Intervet Ireland Limited

ATC kanuni:

QP52AC13

INN (Jina la Kimataifa):

Fenbendazole

Kipimo:

18.75 percent weight/weight

Dawa fomu:

Oral paste

Dawa ya aina:

POM: Prescription Only Medicine as defined in relevant national legislation

Kundi la matibabu:

Horses

Eneo la matibabu:

fenbendazole

Matibabu dalili:

Endoparasiticide

Idhini hali ya:

Authorised

Idhini ya tarehe:

1999-10-01

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Oral Paste 18.75 %w/w
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral paste.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and other equine species
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of immature and mature stages of nematodes of the
gastro-intestinal tract of horses and other equine
species.
Sensitive endoparasites include adult and immature stages of:
Large and small strongyles
Ascarids,
_Oxyuris equi_
_Strongyloides_ spp.
_Dictyocaulus arnfeldi_
Panacur is effective for the treatment of immature and migrating
strongyle infections in equines.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredient.
Each g paste contains:
ACTIVE SUBSTANCE
Fenbendazole
187.5 mg
EXCIPIENTS
Methyl Parahydroxybenzoate
1.7 mg
Propyl Parahydroxybenzoate
0.16 mg
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_2_
_/_
_0_
_7_
_/_
_2_
_0_
_1_
_1_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_0_
_1_
_5_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and
could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
- Underdosing,
which may be due to unde